EPO and anemia (phenotype): In a CKD mouse model, FGF23 signaling inhibition improved anemia and iron deficiency by increasing EPO levels, hemoglobin, red blood cells, bone marrow erythroid progenitors, and driving hematopoietic stem cells to the erythroid lineage [62].